Q1 2021

Filed May 17, 2021 · 10-Q · 47 days after period end · 0001785982-21-000092

Q1 2021 · 10-Q

Revenue—

Net Income

-$1.78M

N/M vs Q1 2020

EPS Diluted

-$0.02

N/M vs Q1 2020

Operating Income-$1,688,911N/M

Operating Cash Flow-$391,100N/M

Same quarter

Metric	Q1 2021	Q1 2020	Q1 2019	Q1 2018
Revenue	—	—	—	$13.32K
Net Income	-$1.78M	-$540.50K	-$191.41K	-$29.61K
EPS Diluted	-$0.02	-$0.01	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR